CT-011

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameCT-011
Drug Alias NameGlypican-3-chimeric-antigen-receptor-T-cell-therapyCAR-GPC3 T Cellsanti-GPC3 CAR TCAR T cells redirected to Glypican-3CSG-GPC-3 +[10] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsWnt signalling pathway inhibitorsGlypican-3 inhibitors
TargetsGlypican-3
Therapy Area/IndicationsSolid tumoursCarcinoma, Squamous CellCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesRenji Hospital Affiliated To Shanghai Jiaotong University School Of MedicineCarsgen Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Hepatocellular
Inactive IndicationsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A
Related LinksN/A